Our doctors are currently seeing patients through in-person and video visits.
When you call to schedule an appointment with our doctors, please let the team know if you want an in-person or video visit. If you request a video visit, our team will walk you through the simple process of arranging one. Call your preferred campus today to schedule an in-person or video visit* appointment.
* This service is open to new and existing patients.
A Leader in the Care of Children with Liver Tumors
Although liver tumors in children are rare (they account for only one to two percent of childhood cancers), they can be very complex, and require a team approach for the best care. Families of children with liver tumors who come to NewYork-Presbyterian/Morgan Stanley Children's Hospital meet with all the members of the healthcare team right from the beginning. Patients and their families come to us from all over the world for our expertise and comprehensive care.
- A Team of Specialists: The pediatric liver tumor team includes an oncologist, hepatologist, pediatric surgeon, liver transplant surgeon, interventional radiologist, nurse practitioner, physician assistant, nutritionist, social worker, and child life specialist. Our team has exceptional experience treating children with hepatoblastoma, hepatocellular carcinoma, sarcomas, and other large tumors affecting the liver. All of your child's team members collaborate regularly throughout your child's treatment to deliver care effectively and compassionately.
- Advancing the Field through Research: We have a robust clinical and translational research program to advance the care of children with liver cancer now and in the future. We offer clinical trials assessing new therapies for challenging pediatric liver tumors, with the goal of improving survival and decreasing the side effects of treatment. Your child may have the opportunity to participate in a clinical trial. Our center is one of the few performing research on hepatoblastoma genetics (e.g. personalized/precision medicine targeting the molecular biology of each patient's tumor), and on developing laboratory models of hepatoblastoma to learn more about the disease.